



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – October 20, 2020

MEDraysintell to showcase its Reports during the EANM virtual congress

MEDraysintell will display its series of market reports and directories during the EANM – European Association of Nuclear Medicine – virtual congress (October 22-30, 2020). <https://eanm20.eanm.org/>. This unique work was recently updated and describes in over 4,000 pages the state-of-the-art in Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy.

If you are looking for the ultimate reference resource in Nuclear Medicine & Cyclotrons, written by experts, **take a look at our virtual booth. Paul-Emmanuel will be delighted to chat with you about the contents and uniqueness of these reports.**

MEDraysintell estimates that the global market for nuclear medicine reached closed to US\$ 6 billion in 2019, growing by approximately 8% in comparison to the year 2018. Radiotherapeutics represented 20% of the total nuclear medicine market and are anticipated to growth strongly during the coming decade.

These reports are intended for those who need to know the competitive environment and the potential evolution in this field at the level of products on the market, molecules under development and associated companies. There is an increasing interest from private investors and conventional pharmaceutical industries for the nuclear medicine market, of course mainly in the therapeutic area. During the past six years, over US\$ 16 billion were invested in M&A transactions in the radiopharmaceutical industry. New opportunities for development, investments, mergers and acquisitions are just popping up.

The **Nuclear Medicine Reports & Directories Edition-2020** is a set of three reports (2,900 pages) providing a comprehensive and exhaustive review of the worldwide nuclear medicine landscape, thru a description of about 830 products, together with a comprehensive profile of nearly 320 companies active in the radiopharmaceuticals industry.

The **Cyclotrons used in Nuclear Medicine Report & Directory Edition-2020** (450 pages) provides an extensive review of all cyclotrons (~1,500) installed or recently sold in all countries and regions of the world with an exhaustive profile of the companies active in this market.

About MEDraysintell

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, cyclotron, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with over 4,000 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the utmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them to better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeated satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. The team's expertise combines a century of experience in radiation healthcare. www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00